<DOC>
	<DOCNO>NCT02567695</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability single 300 mg dose GBT440 administer high strength ( 1 × 300 mg ) capsule versus low strength ( 3 × 100 mg ) capsule formulation healthy fast subject .</brief_summary>
	<brief_title>A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Subject female nonchildbearing potential male , healthy , nonsmoking , 18 60 year old , inclusive , screen Male subject agree use contraception Willing able give write informed consent Evidence history clinically significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History hypersensitivity allergy drug , food , substance History presence abnormal electrocardiogram hypertension History alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction within 1 year screening Participated another clinical trial investigational drug within 30 day ( 5 halflives investigational drug , whichever long ) prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>